Initial Dose Tarlatamab–Associated Tumour Lysis Syndrome in Small Cell Lung Cancer: A Case Report
Katsuhiko Shibata, Hiromu Tanaka, Yusuke Arai, Yusuke Watanuki, Takashi Kokubo, Yo Watanabe, Shingo Nakayama, Takahiro Asami, Takashi Inoue · 2026
Read Initial Dose Tarlatamab–Associated Tumour Lysis Syndrome in Small Cell Lung Cancer: A Case Report by Katsuhiko Shibata, Hiromu Tanaka, Yusuke Arai, Yusuke Watanuki, Takashi Kokubo, Yo Watanabe, Shingo Nakayama, Takahiro Asami, Takashi Inoue (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13310580.txt.
Description
Katsuhiko Shibata and co-authors report a fatal tumor breakdown crisis after a new immune drug in a 2026 case article. Tumor lysis syndrome strikes when cancer cells burst en masse and flood the blood with their contents. It is rare in solid tumors but can hit small cell lung cancer with heavy spread.
A 61-year-old woman whose lung cancer had returned with extensive liver spread received a first 1 mg step-up dose of tarlatamab as second-line care. Mild cytokine release on day two eased with steroids. On day six she abruptly developed breathing failure and clouded consciousness, and blood tests showed the classic lysis pattern with kidney injury; she died that day. The authors urge close watching and prevention in high-burden patients.
Catalog record
| CREATOR | Katsuhiko Shibata, Hiromu Tanaka, Yusuke Arai, Yusuke Watanuki, Takashi Kokubo, Yo Watanabe, Shingo Nakayama, Takahiro Asami, Takashi Inoue |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 11705 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |